tbuckley/cabot-search huggingface dataset:
EXTH-45. THE COMBINATION OF TTFIELDS AND ABT-414 DEMONSTRATE SUPERIOR EFFICACY AGAINST GLIOMA CELLS
Authors: Rosa Schneiderman, Einav Zeevi, Moshe Giladi, Eilon D Kirson, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is the most aggressive primary malignancy of the central nervous system in adults. The prognosis of adult patients with GBM remains poor, even with the best approved therapy which consists of surgical resection followed by radiotherapy with concomitant daily temozolomide chemotherapy, and maintenance treatment with temozolomide and Tumor Treating fields (TTFields). ABT-414 is a novel Antibody–drug conjugates comprised of the microtubule inhibitor, monomethyl auristatin F (MMAF) and ABT-806, an EGFR-targeting antibody. Unlike many other anti-microtubules agents, ABT-414 penetrate through the blood brain barrier and its efficacy is now being tested for the treatment of GBM. The goal of the present study is to test the efficacy of the combination of TTFields and ABT-414 in the U87MGde2-7 glioma cell line expressing the mutant EGFRvIII. TTFields (200 kHz) were applied for 72 hours using the inovitro system. ABT-414 or the isotype control were added to the media. Cell counts and induction of apoptosis were determined at the end of treatment. The combined treatment demonstrated superior efficacy as compared to each treatment alone, leading to a significant reduction in the number of U87MGde2-7 cells (ABT-414 concentrations in the pM range, p<0.01). The combination of TTFields and the isotype control led to a non-significant reduction in the number of cells as compared to TTFields treatment alone. A rapid increase in the number of apoptotic cells was seen for the combination in all tested concentrations. These results demonstrate the combination of TTFields and ABT-414 to be an effective treatment against glioma cells. Furthermore, the combined treatment did not lead to nonspecific activity of the drug. Based on the above, there is a strong rational to continue exploring the potential of combining TTFields and ABT-414 in the clinical settings.
ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)
Authors: Daniela Bota, Annick Desjardins, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Steven D Reich, Nancy Levin, Mohit Trikha
Journal: Neuro-Oncology (2017)

MRZ – an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma preclinical activity – was evaluated in BEV-naïve rGBM patients. Phase 1 (P1) MRZ+BEV, 3 + 3 MRZ dose-escalation (N=6, 3, 3 at 0.55, 0.7, 0.8 mg/m2) followed by dose-expansion (N=24, 0.8 mg/m2). Phase 2 (P2) MRZ monotherapy (N=30, 0.8 mg/m2). Treatments (IV, 28-day (D) cycles): MRZ (10min infusion) D1, 8, 15; BEV (10 mg/kg) D1, 15. Tumor response (RANO criteria) every other cycle; MRZ and BEV PK, and proteasome inhibition in blood evaluated in P1. as of 14Apr2017: P1 mean age 55 yrs, 64% male, mean treatment duration 5.3 cycles, 1 patient active; P2 56 yrs, 57% male, 2.5 cycles, 6 patients active. One DLT (fatigue) in P1 at 0.55 mg/m2, no other DLTs. P1 treatment-related AEs (TRAEs Grade ≥3 in ≥2 patients): hypertension, headache, confusional state, fatigue, hallucination, proteinuria; three Grade 4 SAEs (appendicitis perforated, depressed level of consciousness, not-related; blindness, BEV-related), three Grade 5 SAEs (2 PD, not-related; intracranial hemorrhage, BEV-related). P2 TRAEs (Grade ≥3 in ≥2 patients): fatigue, hallucination, lethargy; one Grade 4 SAE (hallucination). P1 overall response (≥PR) 44% (16/36) including 1 CR, 15 PR; overall survival (OS) at 6/9/12 months (mos) 75/60/39%, median 9.4mos; OS 68/45/15% (median 7.2mos) in unmethylated MGMT (uMGMT, N=22), 78/78/67% (median not reached) in methylated MGMT (N=10). In P2: 1 PR, 6 SD; 4 patients (3 SD, 1 PR) ongoing at 5–10 cycles. P1 patients experiencing ≥1 CNS-related AEs (any grade: ataxia/balance disorder/dizziness/dysarthria/fall/gait disturbance/hallucination) have increased OS (83/74/45%, median 11.4mos, N=23) versus patients without these AEs (59/34/25%, median 6.3mos, N=13). MRZ monotherapy and MRZ+BEV active in rGBM overall and in uMGMT. Possible therapeutic improvement in patients experiencing CNS AEs will be explored in ongoing P2 MRZ+BEV extension allowing intra-patient MRZ dose-escalation if no CNS AE in first cycle (0.8 mg/m2).
Identification of dominant anti-glycan IgE responses in school children by glycan microarray
Authors: Abena S. Amoah, Elias K. Asuming-Brempong, Benedicta B. Obeng, Serge A. Versteeg, Irene A. Larbi, Yvonne Aryeetey, Thomas A.E. Platts-Mills, Adriano Mari, Katarzyna Brzezicka, Ben A. Gyan, Mohamed Mutocheluh, Daniel A. Boakye, Niels-Christian Reichardt, Ronald van Ree, Cornelis H. Hokke, Angela van Diepen, Maria Yazdanbakhsh
Journal: Journal of Allergy and Clinical Immunology (2017)
P1.10-002 Outcome of Pilot RCT in Lung Cancer Surgery Patients Receiving Either Preop Carbohydrate &amp; Postop Nutritional Drinks or Water
Authors: A. Kerr, N. Oswald, J. Webb, S. Kadiri, H. Bancroft, J. Taylor, P. Rajesh, R. Steyn, M. Kalkat, E. Bishay, B. Naidu
Journal: Journal of Thoracic Oncology (2017)
Abstract 16535: Conditional Knockout of the Mitochondrial 18-kDa Translocator Protein Limits Heart Failure
Authors: Phung Thai, Xiyuan Lu, Daniel Daugherty, Wenbin Deng, Donald M Bers, Saul Schaefer
Journal: Circulation (2015)

Introduction: Heart failure results in myocyte and mitochondrial death, and is characterized by abnormalities in mitochondrial calcium handling, energy production, and opening of the mitochondrial permeability transition pore (mPTP). The 18-kDa mitochondrial translocator protein (TSPO) has been shown to be significantly upregulated by heart failure in animals and in explanted hearts from patients, suggesting a vital role for this protein. Hypothesis: In the current experiments, we tested the hypothesis that conditional knockout of the TSPO using Cre inducible TSPO-floxed C57BL/6J mice would limit heart failure resulting from transverse aortic constriction (TAC). Methods: Mice in 4 groups_wild-type (WT) sham, WT TAC, KO sham, and KO TAC_were monitored by weekly echocardiography for 8 weeks, followed by downstream experiments. Results: TAC caused a 46±13% reduction in ejection fraction in WT mice, which was significantly lower in the KO mice (14±10%, P &lt; 0.01, Figure). Strain analysis revealed a significant improvement in radial, longitudinal, and circumferential strain in KO TAC mice, supported by tissue histology finding of significantly less collagen in KO TAC mice. KO TAC mice showed lower heart to body weight and lung to body weight ratios, with no KO TAC mice showing signs of pulmonary edema. Calcium uptake experiment using Rhod-2 AM in isolated cells revealed that KO TAC mice had higher mitochondrial calcium uptake, a crucial finding since mitochondrial calcium uptake has been shown to play a role in energetics and mPTP opening. Conclusion: Genetic modulation of the TSPO limits heart failure due to pressure overload, likely mediated by preserving mitochondrial calcium uptake and energy production, and possibly limiting mPTP opening. These data suggest that pharmacologic interventions that inhibit TSPO expression or function can limit heart failure at the sub-cellular level.
ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS
Authors: Motomasa Furuse, Shinji Kawabata, Naokado Ikeda, Naosuke Nonoguchi, Yoji Tamura, Yoshinaga Kajimoto, Shin-Ichi Miyatake, Toshihiko Kuroiwa
Journal: Neuro-Oncology (2017)

Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab in such patients is unknown. Fifty-two patients with glioma were treated with bevacizumab between June 2013 and February 2016 in our institute. Of these patients, we focused on 29 patients with recurrent glioblastoma. We retrospectively analyzed the efficacy of bevacizumab in patients with recurrent glioblastoma and poor PS classified using the Karnofsky performance status ≤60 in comparison to historical controls which included patients who were not treated with bevacizumab before approval of bevacizumab in our institute. Progression-free survival was significantly longer in the bevacizumab arm than in the control arm only among patients with poor PS (poor PS: 5.3 months vs 2 months, P = 0.0362; good PS: 6.3 months vs. 3.4 months, P = 0.4163). Meanwhile, overall survival was better in the bevacizumab arm for both patients with good and poor PS, although the differences were not significant (good PS: 17.4 months vs. 10.3 months, P = 0.1009; poor PS: 7.8 months vs. 6.1 months, P = 0.4698). Serious adverse events occurred only in patients with poor PS. Bevacizumab extended PFS by 3 months in recurrent glioblastoma patients with poor PS. In consideration of the possibility of serious adverse events, however, bevacizumab use should be carefully considered in patients with poor PS.
Le rotavirus en Espagne (2000-2004): un modèle prédictif pour un système de surveillance
Authors: F J Luquero, J M Eiros, E Sanchez-Padilla, J Castrodeza, F Simón-Soria, R Ortiz de Lejarazu
Journal: Eurosurveillance (2007)

L’infection a rotavirus est une des causes essentielles de gastroenterite aigue et son impact sur les hospitalisations est important. Il n’existe pas de systeme de surveillance homogene pour les infections a rotavirus en Europe. Le but de cette etude est de developper un modele predictif qui permettra une estimation des infections a rotavirus attendues dans la population couverte par un hopital. Une etude sur cinq ans (2000-2004) a ete menee dans un hopital universitaire espagnol. Un test de correlation a ete realise entre les declarations rapportees au Systeme d’information microbiologique (SIM) et les hospitalisations, ainsi qu’une analyse des series temporelles, pour obtenir la tendance et les composants cycliques. Le modele predictif a ete ajuste en utilisant la methode de moindres carres. Une relation directe entre les isolats microbiologiques et les hospitalisations a ete etablie (ρ=0,925; Pl0,001). Un cycle annuel significatif a ete observe avec un pic en fevrier. Les deux principales epidemies survenues au cours de l’etude auraient ete detectees avec le modele predictif. Les cas et hospitalisations attendus des infections a rotavirus ont ete obtenus pour 2005 et 2006. Les notifications des infections a rotavirus declarees au SIM sont compatibles a la mise en place d’un systeme de surveillance hospitalier, cependant, un modele predictif permettant de prevoir les cas attendus est egalement necessaire. Un tel outil sera utile pour evaluer les mesures de prevention prochainement disponibles en Europe, tels que les vaccins anti-rotavirus.
Adjuvant Melanoma Therapy — Head-Spinning Progress
Authors: Lynn M. Schuchter
Journal: New England Journal of Medicine (2017)

Every year in the United States, approximately 87,000 patients receive the diagnosis of melanoma. Although most of these patients are cured with simple excision, those with node-positive, stage III melanoma are at increased risk for distant metastasis and death. To date, the Food and Drug Administration (FDA) has approved three adjuvant therapies for such patients, all of which are immunotherapies: high-dose interferon alfa-2b, pegylated interferon alfa, and high-dose ipilimumab (10 mg per kilogram of body weight).1-3 Concerns about the marginal efficacy of these drugs (especially the interferon-based agents) and considerable toxicity (all three drugs) have limited their use. Therefore, the . . .
NCMP-06. NEUROLOGICAL OUTCOME IN PEDIATRIC CERVICOMEDULLARY TUMORS
Authors: Zsila Sadighi, Elizabeth Curtis, Jennifer Zabrowski, Arzu Onar-Thomas, Raja Khan, Amar Gajjar, Frederick Boop, Paul Klimo, Alberto Broniscer
Journal: Neuro-Oncology (2017)

We present neurological outcomes in pediatric cervicomedullary tumors (CMT). We retrospectively examined neurological outcomes in pediatric CMT from 1998-2015. Neurological severity was measured using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for 11 deficits, Modified Rankin Scale (MRS), and Karnofsky Performance Score (KPS). The data were analyzed using descriptive statistical methods and plots. Thirty-six patients (50% male), median age at cancer diagnosis 7.7 (0.6-17.8) years had median time to last follow-up 6.2 (0.4-26) years. Tumor pathology varied (25% pilocytic astrocytoma, 25% ganglioglioma, 16.7% astrocytoma, 2.8% myxopapillary ependymoma, 2.8% anaplastic ependymoma, 5.6% anaplastic astrocytoma, 5.6 ependymoma, 5.6% glioblastoma multiforme, and 10.9% other). Thirty-five patients had one surgery (11 biopsy, 2 gross total resection, 19 subtotal resection, 3 biopsy plus subtotal resection). Eleven patients had 2 or more surgeries, 12 had chemotherapy, and 24 had radiotherapy. Median MRS was 2 pre-operative, 2 post-operative, and 1.5 at 5 year follow-up (±2.5 years). Median KPS was 80 pre-operative, 80 post-operative, and 85 at 5 year follow-up. Pre-operative deficits were 62.9% motor weakness, 18.5% ataxia/dysmetria, 18.5% movement, 11.4% vocal cord paralysis, 11.4% autonomic, 11.1% sensory, 11.1% facial motor/sensory, 8.6% sleep, and 3.7% oculomotor. Post-operative deficits were 54.8% motor weakness, 29.0% movement, 29.0% ataxia/dysmetria, 22.9% autonomic, 19.4% sensory, 15.6% oculomotor, 12.9% facial motor/sensory, 5.7% sleep, and 3.2% urinary/gastrointestinal. Deficits at 5-year follow-up were 45.8% movement, 41.7% motor weakness, 41.7% ataxia/dysmetria, 20.8% sleep, 16.7% facial sensory/motor, 12.5% hearing loss, 12.5% autonomic, 8.3% vocal cord paralysis, 4.2% hiccups, 4.2% oculomotor, and 4.2% sensory. The majority of deficits were mild to moderate at each time point. Pediatric CMT after surgery may have long-term neurological deficits, most commonly movement disorder, motor weakness, and ataxia/dysmetria. Less common deficits to monitor for are singulitis, vocal cord paralysis, sleep disorder, and autonomic dysfunction.
P1.01-050 Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong
Authors: H. Loong, M. Huang, C. Wong, L. Leung, T. Burke, S. Chandwani, A. Law, S.C. Tan
Journal: Journal of Thoracic Oncology (2017)
P3.01-008 Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced Non-Small Cell Lung Cancer
Authors: Y. Huang, W. Wang, C. Xu, W. Zhuang, Z. Song, Z. Huang, G. Lin, X. Chen, B. Wu, Y. Chen, G. Chen, M. Fang
Journal: Journal of Thoracic Oncology (2017)
Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis
Authors: Vicente Navarro-López, Ana Ramírez-Boscá, Daniel Ramón-Vidal, Beatriz Ruzafa-Costas, Salvador Genovés-Martínez, Empar Chenoll-Cuadros, Miguel Carrión-Gutiérrez, José Horga de la Parte, David Prieto-Merino, Francisco M. Codoñer-Cortés
Journal: JAMA Dermatology (2017)

Oral intake of new probiotic formulations may improve the course of atopic dermatitis (AD) in a young population.To determine whether a mixture of oral probiotics is safe and effective in the treatment of AD symptoms and to evaluate its influence on the use of topical steroids in a young population.A 12-week randomized, double-blind, placebo-controlled intervention trial, from March to June 2016, at the outpatient hospital Centro Dermatológico Estético de Alicante, Alicante, Spain. Observers were blinded to patient groupings. Participants were children aged 4 to 17 years with moderate atopic dermatitis. The groups were stratified and block randomized according to sex, age, and age of onset. Patients were ineligible if they had used systemic immunosuppressive drugs in the previous 3 months or antibiotics in the previous 2 weeks or had a concomitant diagnosis of intestinal bowel disease or signs of bacterial infection.Twelve weeks with a daily capsule containing freeze-dried powder with 109 total colony-forming units of the probiotic strains Bifidobacterium lactis CECT 8145, B longum CECT 7347, and Lactobacillus casei CECT 9104 and maltodextrin as a carrier, or placebo (maltodextrin-only capsules).SCORAD index score and days of topical steroid use were analyzed.Fifty children (26 [50%] female; mean [SD] age, 9.2 [3.7] years) participated. After 12 weeks of follow-up, the mean reduction in the SCORAD index in the probiotic group was 19.2 points greater than in the control group (mean difference, -19.2; 95% CI, -15.0 to -23.4). In relative terms, we observed a change of -83% (95% CI, -95% to -70%) in the probiotic group and -24% (95% CI, -36% to -11%) in the placebo group (P < .001). We found a significant reduction in the use of topical steroids to treat flares in the probiotic arm (161 of 2084 patient-days [7.7%]) compared with the control arm (220 of 2032 patient-days [10.8%]; odds ratio, 0.63; 95% CI, 0.51 to 0.78).The mixture of probiotics was effective in reducing SCORAD index and reducing the use of topical steroids in patients with moderate AD.clinicaltrials.gov Identifier: NCT02585986.
EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS
Authors: Kensuke Tateishi, Julie Miller, Fumi Higuchi, Mara V A Koerner, Nina Lelic, William Curry, Tracy Batchelor, Hiroaki Wakimoto, Andrew S Chi, Daniel Cahill
Journal: Neuro-Oncology (2017)

Mutant IDH1 suppresses normal IDH1 activity and alters the cellular metabolic microenvironment. We have previously identified that steady-state NAD+ level is decreased in endogenous IDH1 mutant cancers. Additionally, we found that inhibitors of the NAD+ biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT) potently depleted NAD+ and selectively induced cytotoxicity in IDH1 mutant cancers. Here, we investigated strategies to further perturb NAD+ metabolism to enhance NAMPT inhibitor efficacy in IDH1 mutant cancers. One major source of intracellular NAD+ consumption is mediated by distinct enzyme complexes of poly(ADP-ribose) polymerase (PARP). We found that temozolomide (TMZ), a commonly-used alkylating chemotherapeutic agent, transiently and potently reduced NAD+ to enhance NAMPT inhibitor efficacy in IDH1 mutant cancers. Mechanistically, TMZ stimulates an acute burst of NAD+ consumption by PARP via activation of DNA damage repair, and as a result, selectively potentiated NAD+ depletion-induced cytotoxicity in IDH mutant cells. In an in vivo IDH1 mutant cancer model, combined treatment with TMZ and NAMPT inhibitor enhanced efficacy compared to each agent alone. Thus, we find chemotherapy induces metabolic stress in IDH1 mutant cancers which can be exploited for therapeutic gain. Targeting of NAD+ homeostasis via convergent metabolic pathways could improve responses to metabolic therapy.
Reply to Vazquez Guillamet <i>et al.</i> and to Magnussen <i>et al.</i>: “Normalization of FEV<sub>1</sub>/FVC Ratio to Greater Than 0.7 Does Not Equal Resolution of Disease” and “Spirometry Variability Must Be Critically Interpreted before Negating a Clinical Diagnosis of Chronic Obstructive Pulmonary Disease”
Authors: Shawn D. Aaron, George A. Whitmore
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
MA 06.06 Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort
Authors: E. Thunnissen, U. Dafni, L. Bubendorf, A. Warth, W. Biernat, S. Pokharel, R. Dziadziuszko, H. Dienemann, R. Cheney, N. Marti, M. Kassapian, S. Finn, K. Kerr, R. Kammler, R. Stahel, S. Peters, F. Etop Lungscape
Journal: Journal of Thoracic Oncology (2017)
Hypercoagulable state as marker of occult cancer in healthy blood donors: data from HYPERCAN Prospective Study
Authors: S. Gamba, D. Raffaeli, M. Marchetti, L. Russo, C.J. Tartari, C. Giaccherini, C. Verzeroli, V. Milesi, S. Brevi, E. Diani, A. Vignoli, G. Sampietro, P. Malighetti, D. Spinelli, A. Falanga
Journal: Annals of Oncology (2017)
P2.03-014 A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations
Authors: K. Baba, Y. Hasegawa, H. Tanaka, K. Taima, Y. Tanaka, M. Itoga, Y. Ishioka, T. Morimoto, H. Nakagawa, S. Takanashi, S. Tasaka
Journal: Journal of Thoracic Oncology (2017)
Deactivation of the NLRP3 inflammasome in infiltrating macrophages by duodenal-jejunal bypass surgery mediates improvement of beta cell function in type 2 diabetes
Authors: Dong Wu, Zhi-bo Yan, Yu-gang Cheng, Ming-wei Zhong, Shao-zhuang Liu, Guang-yong Zhang, San-yuan Hu
Journal: Metabolism (2017)
Staphylococcus aureus resistentes à meticilina productores de leucocidina de Panton-Valentine (PVL-SARM ): situação na Holanda em 2003
Authors: W J B Wannet, M E Heck, G N Pluister, E Spalburg, M G Van Santen, X W Huijsdans, E Tiemersma, A J de Neeling
Journal: Eurosurveillance (2004)

Na Holanda em 2003, a analise dos isolados de Staphylococcus aureus resistentes a meticilina (SARM) revelou que 8% dos isolados procedentes de hospitais carregavam genes para a leucocidina de Panton-Valentine (PVL). A subtipagem molecular mostrou que a maioria dos genotipos de PVL-SARM holandeses correspondiam a tipos epidemicos globais bem conhecidos. As sequencias mais frequentes eram de tipo ST8, ST22, ST30, ST59 e ST80. Na Holanda, os SARM aumentaram de 1% em 2002 a 17% em 2003. E importante notar que a emergencia dos PVL-SARM esta afectando nao so a comunidade, mas tambem os hospitais.
METB-02. A SENSITIVE METABOLIC SIGNATURE TO PREDICT IMMUNE RESPONSE AFTER IMMUNOTHERAPY FOR BRAIN TUMORS
Authors: Farhad Dastmalchi, Aida Karachi, Ram Khattri, Matthew E Merritt, Duane Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2017)

We recently demonstrated that migration of dendritic cells (DCs) to the draining lymph nodes was essential for survival benefit in glioblastoma (GBM) patients receiving DC vaccines. The objective of this project was to develop a sensitive surrogate biomarker for the migration of DCs after vaccination. We developed a robust metabolic analysis of serum and urine after vaccination that reflects immune changes related to vaccination, and can be used as a prediction marker for response after immunotherapy. Myeloid-derived DCs were electroporated with OVA-mRNA and used to vaccinate mice that received OT-1 splenocytes. After vaccination, the animals underwent lymph node and bladder magnetic resonance imaging (MRI) spectroscopy and had collection of urine and serum for NMR analysis. MR spectroscopy of the draining lymph nodes and bladder were feasible in the mice and Immune response after vaccination resulted in changes in fat signals in the lymph nodes of vaccinated mice compared to unvaccinated mice. MR spectroscopy of the bladder was more sensitive and informative with unique spectral signatures that vaccinated animals including increases in urea, taurine, creatinine, and citrate. A more in depth metabolic analysis was performed of urine and serum collected from vaccinated animals before and after vaccination using NMR spectroscopy. The partial least squares analysis revealed a sensitive metabolic signature in animals post-vaccination that significantly distinguished animals pre and post-vaccination. The metabolic signature change was most dramatic at 24 hours post vaccination and slowly returned back to baseline by 7 days post vaccination. The main drivers of the differences included phenylalanine, lactate, glucose, glutamine, leucine and formate. Cellular immunotherapy results in systemic metabolic changes that can serve as biomarkers of effective cellular immunotherapy. These findings have significant translational relevance in predicting patients who will develop an immune response to immunotherapy and ultimately have better outcomes with treatment.